| dbo:abstract
|
- Les inhibiteurs de la recapture de la dopamine, de la sérotonine et de la noradrénaline, aussi appelés inhibiteurs triples, sont une classe d'antidépresseurs qui vont ralentir la recapture de la dopamine par son transporteur : le DAT, la recapture de la sérotonine par le SERT, et la recapture de la noradrénaline par son transporteur : le NET, ce qui va augmenter leur taux dans la fente synaptique. Cette classe de médicaments n'existe pas encore en France mais existe aux États-Unis. (fr)
- A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively. Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission. SNDRIs were developed as potential antidepressants and treatments for other disorders, such as obesity, cocaine addiction, attention-deficit hyperactivity disorder (ADHD), and chronic pain. They are an extension of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) whereby the addition of dopaminergic action is thought to have the possibility of heightening therapeutic benefit. However, increased side effects and abuse potential are potential concerns of these agents relative to their SSRI and SNRI counterparts. The SNDRIs are similar to non-selective monoamine oxidase inhibitors (MAOIs) such as phenelzine and tranylcypromine in that they increase the action of all three of the major monoamine neurotransmitters. They are also similar to serotonin–norepinephrine–dopamine releasing agents (SNDRAs) like MDMA ("ecstasy") and α-ethyltryptamine (αET) for the same reason, although they act via a different mechanism and have differing physiological and qualitative effects. Although their primary mechanisms of action are as NMDA receptor antagonists, ketamine and phencyclidine are also SNDRIs and are similarly encountered as drugs of abuse. (en)
- Os inibidores de recaptação de serotonina-noradrenalina-dopamina (SNDRIs), também conhecidos como inibidores triplos de recaptação (TRI), são uma classe farmacológica composta por drogas que inibem a recaptação dos neurotransmissores monoamínicos: serotonina, noradrenalina e dopamina. Seu mecanismo de ação inibe, ao mesmo tempo, a recaptação neuronal do transportador de serotonina (SERT), noradrenalina (NET) e o dopamina (DAT). A inibição da recaptação desses neurotransmissores aumenta suas concentrações extracelulares e, portanto, estimulam a neurotransmissão serotoninérgica, noradrenérgica e dopaminérgica. (pt)
- 5-羟色胺、去甲肾上腺素和多巴胺再摄取抑制剂（英語：serotonin–norepinephrine–dopamine reuptake inhibitor，SNDRI），也称作三重再摄取抑制剂（TRI），是多种单胺类神经递质的再摄取抑制剂，原理为通过抑制5-羟色胺转运体、去甲肾上腺素转运体和多巴胺转运体体来分别抑制5-羟色胺、 去甲肾上腺素和多巴胺的再摄取。这个作用会增加这些神经递质在突触间隙的浓度。 SNDRI作為一系列疾病的藥物候選而被開發，如抗憂鬱劑和治療肥胖、古柯鹼成癮、注意力缺陷/過動症(ADHD)及慢性疼痛的藥物。SNDRI作為選擇性血清素再吸收抑制劑(SSRIs)及血清素-去甲腎上腺素再吸收抑制劑(SNRIs)的延伸，增加了多巴胺的再吸收抑制作用，這被認為具有增加療效的可能，但副作用及藥物濫用的可能也隨之增加。 (zh)
|
| rdfs:comment
|
- Les inhibiteurs de la recapture de la dopamine, de la sérotonine et de la noradrénaline, aussi appelés inhibiteurs triples, sont une classe d'antidépresseurs qui vont ralentir la recapture de la dopamine par son transporteur : le DAT, la recapture de la sérotonine par le SERT, et la recapture de la noradrénaline par son transporteur : le NET, ce qui va augmenter leur taux dans la fente synaptique. Cette classe de médicaments n'existe pas encore en France mais existe aux États-Unis. (fr)
- 5-羟色胺、去甲肾上腺素和多巴胺再摄取抑制剂（英語：serotonin–norepinephrine–dopamine reuptake inhibitor，SNDRI），也称作三重再摄取抑制剂（TRI），是多种单胺类神经递质的再摄取抑制剂，原理为通过抑制5-羟色胺转运体、去甲肾上腺素转运体和多巴胺转运体体来分别抑制5-羟色胺、 去甲肾上腺素和多巴胺的再摄取。这个作用会增加这些神经递质在突触间隙的浓度。 SNDRI作為一系列疾病的藥物候選而被開發，如抗憂鬱劑和治療肥胖、古柯鹼成癮、注意力缺陷/過動症(ADHD)及慢性疼痛的藥物。SNDRI作為選擇性血清素再吸收抑制劑(SSRIs)及血清素-去甲腎上腺素再吸收抑制劑(SNRIs)的延伸，增加了多巴胺的再吸收抑制作用，這被認為具有增加療效的可能，但副作用及藥物濫用的可能也隨之增加。 (zh)
- A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively. Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission. (en)
- Os inibidores de recaptação de serotonina-noradrenalina-dopamina (SNDRIs), também conhecidos como inibidores triplos de recaptação (TRI), são uma classe farmacológica composta por drogas que inibem a recaptação dos neurotransmissores monoamínicos: serotonina, noradrenalina e dopamina. (pt)
|
